New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 1, 2007, Pages 99-107

  Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Aspergillus; Candida; galactomannan assay; glucan assay; hematopoietic stem cell transplant; invasive fungal infection; targeted therapy

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; GLUCAN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; ASPERGILLOSIS; ASPERGILLUS; BIOASSAY; CANCER MORTALITY; CANCER SURVIVAL; CANDIDA; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE MARKER; DRUG EFFICACY; FUNGAL COLONIZATION; FUNGUS GROWTH; FUNGUS IDENTIFICATION; FUSARIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION CONTROL; LOW DRUG DOSE; MORBIDITY; MYCOSIS; NOCARDIA; PENICILLIUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; TRICHOSPORON;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIALS; GLUCANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MANNANS;

EID: 33847205306     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.11.008     Document Type: Review

References (52)

1. Pfaller M.A., Pappas P.G., and Wingard J.R. Invasive fungal pathogens: current epidemiological trends. Clinical Infectious Diseases 43 (2006) S3-S14
2. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy 49 (2005) 3640-3645
3. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clinical Infectious Diseases [in press].
4. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. The American Journal of Medicine 72 (1982) 101-111
5. EORTC International Antimicrobial Therapy Cooperative Project Group. Empiric antifungal therapy in febrile granulocytopenic patients. The American Journal of Medicine 86 (1989) 668-672
6. Wingard J.R. Empirical antifungal therapy in treating febrile neutropenic patients. Clinical Infectious Diseases 39 supplement 1 (2004) S38-S43
7. De Pauw B.E. Between over- and undertreatment of invasive fungal disease. Clinical Infectious Diseases 41 (2005) 1251-1253
8. Caillot D., Casasnovas O., Bernard A., et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. Journal of Clinical Oncology 15 (1997) 139-147
9. Greene R. The radiological spectrum of pulmonary aspergillosis. Medical Mycology 43 supplement 1 (2005) S147-S154
10. Alexander B.D., and Pfeiffer R.M. Contemporary tools for diagnosis and managment of invasive mycoses. Clinical Infectious Diseases 43 (2006) S15-S27
11. Marr K.A., Balajee S.A., McLaughlin L., et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. The Journal of Infectious Diseases 190 (2004) 641-649
12. Hope W.W., Walsh T.J., and Denning D.W. Laboratory diagnosis of invasive aspergillosis. The Lancet Infectious Diseases 5 (2005) 609-622
13. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clinical Infectious Diseases 39 (2004) 199-205
14. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clinical Infectious Diseases 41 (2005) 654-659
15. Mennink-Kersten M.A., Donnelly J.P., and Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. The Lancet Infectious Diseases 4 (2004) 349-357
16. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clinical Infectious Diseases 41 (2005) 1242-1250
17. Hebart H., Klingspor L., Klingebiel T., et al. PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: Preliminary results of a prospective study. Blood 104 (2004) 59a (abstract)
18. Bow E.J., Laverdiere M., Lussier N., et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94 (2002) 3230-3246
19. Kanda Y., Yamamoto R., Chizuka A., et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 89 (2000) 1611-1625
20. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases 34 (2002) 909-917
21. Grow W.B., Moreb J.S., Roque D., et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplantation 29 (2002) 15-19
22. Winston D.J., Maziarz R.T., Chandrasekar P.H., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Annals of Internal Medicine 138 (2003) 705-713
23. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 1527-1533
24. Cornely O., Maertens J., Winston D., et al. Posaconazole vs standard azole (FLU/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high-risk neutropenic patients: results of a randomized, multicenter trial. Blood 106 (2005) 524a (abstract)
25. Ullmann A.J., Lipton J.H., Vesole D.H., et al. A multicenter trial of oral posaconazole vs fluconazole for the prophylaxis of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation with graft-vs-host disease. Interscience Conference on Antimicrobial Agents and Chemotherapy (2005) (abstract M-716)
26. Wingard J.R. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clinical Infectious Diseases 39 supplement 4 (2004) S176-S180
27. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinical Infectious Diseases 39 (2004) 1407-1416
28. Mattiuzzi G.N., Alvarado G., Giles F.J., et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrobial Agents and Chemotherapy 50 (2006) 143-147
29. Penack O., Reinwald M., Schmidt-Hieber M., et al. Low dose liposomal amphotericin B (L-AmB) as prophylaxis of invasive fungal infections (IFI) in patients (pts) with prolonged neutropenia (N): results from a phase-III trial. Interscience Conference on Antimicrobial Agents and Chemotherapy (2005) (abstract M-975)
30. Mattiuzzi G.N., Estey E., Raad I., et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97 (2003) 450-456
31. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. The Journal of Infectious Diseases 191 (2005) 1350-1360
32. Mattner F., Weissbrodt H., and Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scandinavian Journal of Infectious Diseases 36 (2004) 312-314
33. Imhof A., Balajee S.A., Fredricks D.N., et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clinical Infectious Diseases 39 (2004) 743-746
34. Marty F.M., Cosimi L.A., and Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. The New England Journal of Medicine 350 (2004) 950-952
35. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clinical Infectious Diseases 39 (2004) 584-587
36. Kobayashi K., Kami M., Murashige N., et al. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 89 (2004) ECR42
37. Vigouroux S., Morin O., Moreau P., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clinical Infectious Diseases 40 (2005) e35-e37
38. Wingard J.R. Zygomycosis: epidemiology and treamtnet options. Johns Hopkins Advanced Studies in Medicine 6 (2006) S526-S530
39. Bennett J.E., Dismukes W.E., Duma R.J., et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. The New England Journal of Medicine 301 (1979) 126-131
40. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. The New England Journal of Medicine 331 (1994) 1325-1330
41. Schaffner A., and Frick P.G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. The Journal of Infectious Diseases 151 (1985) 902-910
42. Steinbach W.J. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Current Drug Targets Infectious Disorders 5 (2005) 203-210
43. Wheat L.J. Combination therapy for aspergillosis: is it needed, and which combination?. The Journal of Infectious Diseases 187 (2003) 1831-1833
44. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., et al. Combination antifungal therapy. Antimicrobial Agents and Chemotherapy 48 (2004) 693-715
45. Kontoyiannis D.P., and Lewis R.E. Toward more effective antifungal therapy: the prospects of combination therapy. British Journal of Haematology 126 (2004) 165-175
46. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., and Ghannoum M.A. Combination treatment of invasive fungal infections. Clinical Microbiology Reviews 18 (2005) 163-194
47. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they?. The Journal of Antimicrobial Chemotherapy 54 (2004) 854-869
48. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81 (2006) 320-326
49. Aliff T.B., Maslak P.G., Jurcic J.G., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 (2003) 1025-1032
50. Kontoyiannis D.P., Hachem R., Lewis R.E., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299
51. Marr K.A., Boeckh M., Carter R.A., et al. Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Diseases 39 (2004) 797-802
52. Caillot D., Thiebault A., Herbrecht R., et al. Liposomal amphotericin B in combination with caspofungin versus liposomal amphotericin B high dose regimen for the treatment of invasive aspergillosis in immunocompromised patients: randomized pilot study (Combistrat trial). Focus on Fungal Infections 16 (2006) 174 (abstract P-004)